Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "eisai"

Eisai divests US Zonegran rights to Concordia07-09-2014
Pharma Letter

Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin)...

Tokyo -- (JCN Newswire) -- Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "Halaven") and lenvatinib ... Stockwatch, 9 hours ago
[x]  

16 images for eisai

Pharma Letter, 1 week ago
Avid, 1 week ago
Drug Discovery and Development, 1 week ago
Asian Scientist, 2 weeks ago
OncLive, 2 weeks ago
I Stock Analyst, 2 weeks ago
ABC News 4 Charleston, 2 weeks ago
Pharma Letter, 4 weeks ago
Pharma Letter, 4 weeks ago
PM 360, 1 month ago

New Halaven(R) (Eribulin) and Lenvatinib Data to be Presented at ESMO 2014 Demonstrates Strength of Eisai Oncology Portfolio

/PRNewswire/ -- FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Wealth of data highlights Eisai's commitment to people with cancer and their families Nine abstracts for Eisai's oncology portfolio are to be presented during the European ...
 Individual.com19 hours ago New Halaven® (Eribulin) and Lenvatinib Data to be Presented at ESMO 2014 Demonstrates Strength of Eisai Oncology Portfolio  Sys-Con Australia18 hours ago
Motley Fool

Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's Qsymia Witness Declining Prescriptions

US Food and Drug Administration has approved Novo Nordisk and Orexigen Therapeutics newly developed obesity drugs on September 11. The drugs will compete with Arena-Eisai's Belviq and Vivus's Qsymia, whose US retail prescriptions have been declining ...
 Bidness Etc4 days ago FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug  Motley Fool5 days ago Takeda preps to launch Orexigen's obesity drug Contrave as Novo's Saxenda looms  FiercePharma6 days ago Orexigen Therapeutics, Inc., Novo Nordisk A/S Seek To Enter Still Struggling Obesity Market This Week  BioSpace1 week ago
Asian Scientist

Eisai enters into an agreement with Kyorin Pharmaceutical

Eisai Co., Ltd. and Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc., have entered into an agreement concerning the evaluation and use of Eisai's compound library, which includes natural products, by Kyorin to ...
 Individual.com5 days ago EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS  PipelineReview1 week ago EISAI : AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS  4 Traders6 days ago Eisai & Zeria To Develop Gastic Acid Drug  Asian Scientist2 weeks ago
[x]  
Securities Technology Monitor

Japan Tobacco Inc. (2914) - Financial and Strategic SWOT Analysis Review

Ajinomoto Co., Inc. Altria Group, Inc. Asahi Breweries, Ltd. Dimon Eisai Co., Ltd. Golden Tobacco Limited provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by The ...
 Research and Markets1 day ago Eisai sells U.S. rights to epilepsy drug [The Record (Hackensack, N.J.) :: ]  BusinessWeek1 week ago Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc.  Securities Technology Monitor2 weeks ago Eisai Inc. Sells U.S. Rights To Zonegran® (zonisamide) Capsules To Concordia Pharmaceuticals  BioSpace1 week ago
[x]  

Rights to Zonegran Sold by Eisai

Jennifer Genova (compiled from ) , New Jersey Law Journal September 5, 2014 | 0 Comments share Thank you for sharing! Your article was successfully shared with the contacts you ...
 New Jersey Law Journal1 week ago Concordia to acquire US and Puerto Rican rights of Zonegran from Eisai  Pharmaceutical Business Review1 week ago GE Capital Provides Facility for Concordia's Zonegran Buy  ABF Journal2 weeks ago

Eisai submits applications for approval of thyroid cancer drug to FDA and EMA

Compared to placebo, lenvatinib achieved a statistically significant improvement (Hazard Ratio (HR) 0.21, p0.0001) in progression free survival (PFS), which was the primary objective of the study. The most common lenvatinib treatment-related adverse ...
 Individual.com2 weeks ago

FDA clears generic Dacogen

The FDA approves InnoPharma's ANDA for decitabine for injection, a generic version of Eisai's Dacogen . Sandoz ( NVS -0.2% ) will market and distribute the product in the U.S. Decitabine is a treatment for patients with myleodysplastic syndromes ...
 Seeking Alpha2 weeks ago 9/15/14 - InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®  Pharmacy Choice2 days ago FDA News Roundup: Merck, UCB, Pfizer, Ipsen, And More  Pharmaceutical Online1 week ago InnoPharma : FDA Okays Decitabine For Injection, Generic Version Of Dacogen  Pharmacy Choice2 weeks ago
[x]  
Pharma Letter

Eisai's lenvatinib shows significant improvement in progression-free survival in some cancers

Results from a Phase III study of Japanese drug major Eisai's (TYO: 4523) cancer therapy lenvatinib have shown a significant improvement in progression-free survival in radioiodine-refractory differentiated thyroid cancer. Analyses of subgroups ...
 Pharma Letter1 week ago Eisai's Phase III lung cancer study fails to meet primary endpoint  Individual.com3 weeks ago Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses  Individual.com1 week ago
[x]  

Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium

WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the ...
 Noodls5 days ago Eisai Inc. Release: Lorcaserin HCl Data To Be Presented At The American Society of Bariatric Physicians'  BioSpace1 week ago ARENA PHARMACEUTICALS : Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium  4 Traders5 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less